ライフサイエンスコーパス: IL-6 receptor

1 pression of CD27, and high levels of IgM and IL-6 receptor.

2 ulation and IL-6-induced endocystosis of the IL-6 receptor.

3 f the nonsignaling gp80 alpha-subunit of the IL-6 receptor.

4 only when it was in complex with the soluble IL-6 receptor.

5 gp130, the signal-transducing subunit of the IL-6 receptor.

6 ndothelial cells through a newly constituted IL-6 receptor.

7 on in hepatic cells is equivalent to that of IL-6 receptor.

8 ression of the plasma membrane high-affinity IL-6 receptor.

9 h factor receptor-bound protein 2 (GRB2) and IL-6 receptor.

10 e formation of complexes of IL-6 and soluble IL-6 receptor.

11 increase in the expression of high-affinity IL-6 receptors.

12 ilizumab directed against the interleukin 6 (IL-6) receptor.

13 IL-6 effect was abrogated by excess soluble IL-6 receptor (500 microg/l).

14 6 were mediated by complexation with soluble IL-6 receptor, a process known as trans-signaling.

15 veral factors, including interleukin (IL)-1, IL-6, receptor activator of NF-kappaB (RANK) ligand, par

16 PAC inhibits interleukin 6 (IL-6) receptor activity and pathogenic T helper cell 1 (

17 demonstration of increased expression of the IL-6 receptor after loss of sex steroids provides an exp

18 the non-signaling membrane-bound or soluble IL-6 receptor alpha (IL-6R, sIL-6R), which is referred t

19 ted mice with deletion of the membrane bound IL-6 receptor alpha (IL-6Ralpha) on neural cells, on per

20 The association of IL-6 and IL-6 receptor alpha (IL-6Ralpha) with asthma was reporte

21 nstrate that T cell-specific deletion of the IL-6 receptor alpha chain (IL-6Ralpha) results in impair

22 ignal transducer but is not dependent on the IL-6 receptor alpha subunit (IL-6R, gp80) that is requir

23 reduction in the amount of mRNA encoding the IL-6 receptor alpha subunit and IL-6 binding activity.

24 requirement for transcription is the soluble IL-6 receptor alpha, which translocates to endothelial c

25 Using their IL-6 receptor alpha-chain (IL-6Ralpha), Sirpalpha(+) DCs

26 n lower expression of the genes encoding the IL-6 receptor alpha-chain (Il6ra) and the IL-6 signal tr

27 nor O-linked glycosylation is necessary for IL-6 receptor alpha-dependent binding to gp130 or signal

28 ot an agonist for this, but we found soluble IL-6 receptor alpha-subunit (IL-6Ralpha), with their con

29 Diminished hepatitis in IL-6-deficient, anti-IL-6 receptor alpha-treated, ovariectomized, or male mic

30 nstruct a model of IL-6 interacting with the IL-6 receptor (alpha-chain) and gp130 (beta-chain) that

31 The interleukin (IL)-6/IL-6 receptor-alpha (IL-6Ralpha)/signal transduction and

32 cing chain by IL-6 and a soluble form of the IL-6 receptor-alpha (sIL-6Ralpha) binding subunit.

33 romal cells acted cooperatively with soluble IL-6 receptor-alpha and thermally induced gp130 to promo

34 r both lymphoid and myeloid fates, expressed IL-6 receptor-alpha chain and responded to IL-6 by phosp

35 scular adhesion were induced by IL-6/soluble IL-6 receptor-alpha fusion protein in mouse tumors and p

36 g pathway, including increased expression of IL-6 receptor-alpha/gp80, activation of the signal trans

37 edly induced mIndy transcription through the IL-6 receptor and activation of the transcription factor

38 F in the peritoneum, do not bear the cognate IL-6 receptor and are thus unable to respond to classic

39 ean winter, with increased levels of soluble IL-6 receptor and C-reactive protein, risk biomarkers fo

40 ction of IL-6 with concomitant expression of IL-6 receptor and gp130 suggest that these factors may p

41 could be rescued by the addition of soluble IL-6 receptor and IL-6 or by retroviral transduction of

42 signaling include antibodies to IL-6 and the IL-6 receptor and inhibitors of janus kinases; several o

43 toplasmic domain of the gp130 subunit of the IL-6 receptor and is different from the SH2 domain-conta

44 omatin, but did not affect the expression of IL-6 receptor and phosphorylation of JAK/STAT3, MAPK, an

45 lassic signaling using the membrane-anchored IL-6 receptor and trans-signaling using its soluble form

46 Here we demonstrate loss of interleukin 6 (IL-6) receptor and IL-6-responsive colony-forming units

47 blotting; however, lower production of both IL-6-receptor and Stat3 explains, in part, reduced activ

48 dothelial cell-derived IL-6 activates IL-6R (IL-6 Receptor) and signal transducer and activator of tr

49 lizumab (TCZ), a monoclonal antibody against IL-6 receptor, and are due in part to the prolongation o

50 The OPC cell lines used express the IL-6 receptor, and IL-6 stimulation of these cells cause

51 IL-6, IL-6 receptor, and phospho-signal transducer and activat

52 s of the gp130 subunit of the interleukin-6 (IL-6) receptor, and a seven amino acid STAT1 recruitment

53 d soluble IL-1 receptor II; IL-6 and soluble IL-6 receptor; and IL-10.

54 nhibition (atacicept) and IL-6 as opposed to IL-6 receptor antagonism, have also been evaluated.

55 The IL-6 receptor antagonist tocilizumab could potentially d

56 Rapamycin and the IL-6 receptor antagonist Tocilizumab reduce alveolar typ

57 Moderate-to-severe CRS is managed with the IL-6 receptor antagonist tocilizumab with or without cor

58 cytokine in the toxicity response, using the IL-6 receptor antagonist tocilizumab.

59 specific antibodies, IL-12/23 antibodies, an IL-6 receptor antagonist, a sphingosine-1-phosphate agon

60 research questions: (1) Does interleukin 6 (IL-6) (receptor) antagonist therapy reduce mortality in

61 ding later confirmed in randomised trials of IL-6 receptor antagonists (IL6RAs).

62 hese data suggest that a randomised trial of IL-6 receptor antagonists in sepsis should be considered

63 to the effect seen in severe COVID-19, where IL-6 receptor antagonists were shown to improve survival

64 de effects in COVID-19 patients treated with IL-6 (receptor) antagonists compared to patients not tre

65 tients compared to patients not treated with IL-6 (receptor) antagonists; and (2) is there an increas

66 onists compared to patients not treated with IL-6 (receptor) antagonists?

67 as a heterogenous treatment effect with anti-IL-6 receptor antibodies between males and females; with

68 rmeabilized osteoclasts incubated with anti- IL-6 receptor antibodies revealed intense, strictly peri

69 For patients who did not receive anti-IL-6 receptor antibodies, the risk of death was slightly

70 )), whereas in patients who did receive anti-IL-6 receptor antibodies, the risk was lower in males (H

71 of which 58% were male and 15% received anti-IL-6 receptor antibodies.

72 d this toxicity was strongly inhibited by an IL-6 receptor antibody (tocilizumab) and less well by TN

73 is study did not reveal any evidence that an IL-6 receptor antibody affects behavioral outcomes in sc

74 gration when added to uninfected HPNCs; anti-IL-6 receptor antibody prevented these changes.

75 Importantly, an anti-IL-6 receptor antibody prevented virus-induced perineuri

76 : the complement C5 antibody eculizumab, the IL-6 receptor antibody satralizumab, the B cell-depletin

77 Inhibition of IL-6 signaling with the anti-IL-6 receptor antibody tocilizumab has provided some cli

78 interaction between biological sex and anti-IL-6 receptor antibody treatment with respect to hospita

79 ibodies between males and females; with anti-IL-6 receptor antibody use having a greater benefit in p

80 significant interaction between sex and anti-IL-6 receptor antibody use on progression to respiratory

81 Rationale: Tocilizumab, an anti-IL-6 receptor antibody, had no statistically significant

82 purpose of this trial was to test whether an IL-6 receptor antibody, tocilizumab, would improve resid

83 immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids,

84 nt humanized monoclonal antibody against the IL-6 receptor approved for treatment of rheumatoid arthr

85 monoclonal antibodies targeting IL-6 and the IL-6 receptor are also being studied for the management

86 , an anti-inflammatory cytokine, and soluble IL-6 receptor are associated with systemic juvenile rheu

87 We show that IL-6 receptors are present in intestinal epithelia in a

88 IL-6 receptors are present on pituitary corticotrophs an

89 effect required NGF or NT-3 but not soluble IL-6 receptor as cofactors.

90 RI), IL-1RII, TNF receptor II (TNFR II), and IL-6 receptor as well as the level of proinflammatory cy

91 that sex steroids regulate expression of the IL-6 receptor as well.

92 was associated with a 2-4-fold reduction of IL-6 receptor at protein and mRNA levels in SGN-40-treat

93 neutralizing antibodies directed against the IL-6 receptor block Rac1-induced STAT3 activation.

94 desensitization strategies, the addition of IL-6 receptor blockade resulted in desensitization with

95 e and immunoabsorption as well as subsequent IL-6 receptor blockade through tocilizumab, a complete a

96 sults from the recent clinical studies using IL-6 receptor blockade, and describe potential mechanism

97 ar1(-/-)) or by combining anti-PD-1 and anti-IL-6-receptor blockade.

98 he IL-1 receptor antagonist anakinra and the IL-6 receptor blocker tocilizumab.

99 uppressive function on the expression of the IL-6 receptor by T cells.

100 eptor signaling complexes with the synthetic IL-6 receptor chain SyCyR(gp130).

101 but failed to affect the mRNA expression of IL-6 receptor chains or activation of JAK2 and STAT3.

102 Furthermore, cholangiocytes possessed the IL-6 receptor complex subunits and intact signaling mech

103 e the nonsignaling gp80 alpha subunit of the IL-6 receptor complex.

104 ecifically mediated by signaling through the IL-6 receptor complex.

105 equential assembly of a functional hexameric IL-6 receptor complex.

106 gnaling driven by CD4 T cell-derived soluble IL-6 receptor complexed with fibroblast-derived IL-6 pro

107 ditional knockout (cKO) model with selective IL-6 receptor deletion in T cells (IL-6R-cKO), we demons

108 Inhibition of IL-6 receptor demonstrated to reduce periodontal inflamm

109 ies against IL-6 or the gp130 subunit of the IL-6 receptor did not attenuate ET-1-induced collagen ac

110 mab; however, he had rapid improvement after IL-6 receptor-directed therapy with tocilizumab.

111 Since the IL-6 receptor does not contain binding sites for the p85

112 Anti-IL-6 antibodies or blocking the IL-6 receptors elicits reduced collagen synthesis, sugge

113 Here, we devised anti-IL-6 receptor eluting gelatin methacryloyl (GelMA) bioma

114 al practice by immunotherapy that blocks the IL-6 receptor encoded by IL6R We describe two patients w

115 e found that IL-2 and TGF-beta down-regulate IL-6 receptor expression and IL-6 signaling.

116 IL-6 receptor expression in single osteoclasts was confi

117 ediated increases in transport by increasing IL-6 receptor expression on the cell surface.

118 roliferative disorders, viral IL-6 and human IL-6 receptor expression was examined.

119 ne representing the only site of unequivocal IL-6 receptor expression.

120 tentiation is likely due to the induction of IL-6-receptor expression as well as prolonged intensity

121 uingly, IL-6 trans-signaling via the soluble IL-6 receptor, facilitated by elevated levels of IL-6, a

122 esses targeting plasma cell and interleukin (IL)-6 receptor for desensitization in a sensitized nonhu

123 (vIL-6), which does not require the cellular IL-6 receptor for binding to the ubiquitously expressed

124 Treating mice with soluble IL-6 receptor fusion protein or silencing STAT3 in tumor

125 leotide polymorphisms (SNPs) in and near the IL-6 receptor gene (IL6R), including the non-synonymous

126 ion results in the induction of the IL-6 and IL-6 receptor genes and neutralizing antibodies directed

127 l effect of inflammatory markers (CRP, IL-6, IL-6 receptor, GlycA) on the cognitive functions examine

128 RNA of the signal-transducing subunit of the IL-6 receptor (gp130) in cells of the bone marrow stroma

129 ted by the signal-transducing subunit of the IL-6 receptor, gp130, or by co-transfected IL-3 receptor

130 By circumventing IL-6-receptor-gp130-coupled signaling with ectopic expre

131 data suggest tissue-specific differences in IL-6-receptor-gp130-coupled signaling, thereby limiting

132 We determined the role of IL-6-receptor-gp130-Stat3 signaling in IL-6 activation o

133 Stem-like and progenitor cells expressed the IL-6 receptor gp80 with concomitant expression of pSTAT3

134 dence that the ligand-binding subunit of the IL-6 receptor (gp80) is a limiting factor for the action

135 effect because IFN-alpha down-regulates the IL-6 receptor, gp80.

136 a humanized monoclonal antibody against the IL-6 receptor, has shown an excellent response.

137 s have been observed in association with the IL-6 receptor; however, inhibition of Src kinases by Csk

138 A functional amino acid change in the IL-6 receptor (IL-6R Asp358Ala; rs2228145) was significa

139 itigated by a common germline variant of the IL-6 receptor (IL-6R p.D358A).

140 An antibody to the IL-6 receptor (IL-6R) alpha subunit effectively neutrali

141 kin-6 (IL-6) trans-signaling via the soluble IL-6 receptor (IL-6R) and robustly support adult neuroge

142 ynthesis of interleukin-6 (IL-6) and soluble IL-6 receptor (IL-6R) and stimulated Janus kinase-2 (JAK

143 Key substrates of ADAM17 are the IL-6 receptor (IL-6R) and TNF-alpha.

144 liminary results have been obtained with the IL-6 receptor (IL-6R) antagonist tocilizumab for the tre

145 e expression of major components of the IL-6/IL-6 receptor (IL-6R) axis.

146 L-6 can mediate proinflammatory effects, and IL-6 receptor (IL-6R) blockade as a treatment for inflam

147 The current study evaluated the effect of IL-6 receptor (IL-6R) blockade with an antiYIL-6R monocl

148 ly competes for binding to the cytokine with IL-6 receptor (IL-6R) by using side chains of two CDR re

149 DC-driven classical signaling after targeted IL-6 receptor (IL-6R) deletion in T cells eliminated pat

150 FN-alpha growth-inhibited cell lines reduced IL-6 receptor (IL-6R) expression, IFN-alpha also reduced

151 A variant in the IL-6 receptor (IL-6R) gene increases asthma risk and is

152 New therapies blocking the IL-6 receptor (IL-6R) have recently become available and

153 d by membrane-bound and soluble forms of the IL-6 receptor (IL-6R) in processes called classic and tr

154 atitis has been reported after initiation of IL-6 receptor (IL-6R) inhibitors (IL-6Ri), while genetic

155 by way of antibody-mediated blockade of the IL-6 receptor (IL-6R) markedly reduces pathologic damage

156 ession in the normal liver, but both met and IL-6 receptor (IL-6R) mRNA are detectable; met mRNA is e

157 atibility between host rodent IL-6 and human IL-6 receptor (IL-6R) on donor hepatocytes.

158 Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specif

159 Moreover, antibodies specific to the IL-6 receptor (IL-6R) or the gp130 subunit were capable

160 efined, nor has the behavior of the specific IL-6 receptor (IL-6R) or the signal transducer gp130.

161 a receptor complex consisting of the cognate IL-6 receptor (IL-6R) or the soluble IL-6 receptor (sIL-

162 Interleukin-6 (IL-6)/IL-6 receptor (IL-6R) plays a major role in autocrine/pa

163 This IL6R coding change increases IL-6 receptor (IL-6R) shedding and promotes IL-6 transsi

164 and Th17 polarization requires an additional IL-6 receptor (IL-6R) signal.

165 wth factor (IGF)/IGF-1 receptor (IGF-1R) and IL-6 receptor (IL-6R) signaling cascades, antiapoptotic

166 -regulation and crosstalk of the AMR and the IL-6 receptor (IL-6R) to induce JAK2-STAT3-TPO activatio

167 monoclonal antibodies directed at IL-6, the IL-6 receptor (IL-6R), and Janus kinase inhibitors.

168 : classical signaling via its membrane-bound IL-6 receptor (IL-6R), and trans-signaling via a natural

169 e clinical usage of monoclonal antibodies to IL-6 receptor (IL-6R), designed to block IL-6 pathways.

170 would interact with the specific alpha-chain IL-6 receptor (IL-6R), is accessible and not occupied by

171 Expression of IL-6, IL-6 receptor (IL-6R), or glycoprotein 130, as well as I

172 Furthermore, we identified the IL-6 receptor (IL-6R), which mediates IL-6-dependent STA

173 pilot study of DES using a novel drug (anti-IL-6 receptor (IL-6R),Tocilizumab [TCZ]) + intravenous I

174 tocytes also do not show activation of other IL-6 receptor (IL-6R)-mediated Janus kinase substrates,

175 d, signal-transducing receptor gp130 and the IL-6 receptor (IL-6R).

176 xamer, formed by the association of two IL-6.IL-6 receptor (IL-6R).gp130 trimers, with gp130 being th

177 nction in 2 ways: by directly binding to the IL-6 receptor (IL-6R; CD126) or via trans-signaling, in

178 is not dependent on the structurally related IL-6 receptor (IL-6R; gp80) subunit of the receptor-sign

179 signaling) or soluble (trans-signaling; TS) IL-6 receptors (IL-6Rs) to regulate liver injury respons

180 hybridoma cell line, B9, and that the gp80 (IL-6 receptor [IL-6R]) component of the IL-6 receptor-si

181 Among these is tocilizumab (anti-IL-6 receptor [IL-6R]) which holds promise for modulatin

182 a role in cytokine signaling, including the IL-6 receptor, IL-1 receptor type I, and IL-1 receptor t

183 an ability of interferon-alpha and a soluble IL-6 receptor/IL-6 (sIL-6R alpha/IL-6) trans-signaling c

184 ited adipocyte IL-6 expression and IL-6 plus IL-6 receptor (IL6R) in myocytes and blood.

185 elated common variants in the interleukin-6 (Il-6) receptor (IL6R) gene to plasma C-reactive protein

186 ack loops, in part by directly targeting the IL-6 receptor (IL6RA) gene, and, thus, amplifying IL-6 a

187 We demonstrate a higher ratio of SOCS3 to IL-6 receptor in adult monocytes than in fetal monocytes

188 orms a complex with the gp130 subunit of the IL-6 receptor in an IL-6-dependent manner.

189 ting OXPHOS in the young TME or blocking the IL-6 receptor in the aged TME reduces the age-specific p

190 ially due to increased expression of soluble IL-6 receptor in the brain relative to the spinal cord t

191 Neutralizing autocrine IL-6 and/or blocking IL-6 receptors in IL-6(+)/gp80(+) MCL cells inhibited ce

192 humanised monoclonal antibody targeting the IL-6 receptor, in patients with generalised myasthenia g

193 ther oncostatin M (OSM) or IL-6 plus soluble IL-6 receptor increased the levels of p21 mRNA and prote

194 we hypothesised that, in these patients, the IL-6 receptor inhibitor tocilizumab would be more effect

195 found that these cells synthesized IL-6 and IL-6 receptors; interruption of this pathway by IL-6 ant

196 The increased expression of IL-6 receptor is correlated with increased proliferation

197 The concentration of IL-6 receptor is increased eightfold in the prostate can

198 Signaling by the IL-6 receptor is mediated through the signal transducing

199 lobal IL-1 receptor gene knockout or central IL-6 receptor knockdown showed attenuated decrease in fo

200 st AILI was abolished in hepatocyte-specific IL-6 receptor knockout mice.

201 Importantly, blockade of the IL-6 receptor led to diminished swelling of a control CH

202 ncrease: 2.3, 1.4-3.8, P = .001) and soluble IL-6 receptor level was associated within 6 years after

203 ptin binding and responded to leptin with an IL-6 receptor-like signaling that includes the activatio

204 these studies suggest that blocking IL-1 or IL-6 receptors may improve the regenerative capacity of

205 We hypothesised that anti-IL-6 receptor monoclonal antibodies are associated with

206 S) treated with the anti-interleukin-6 (anti-IL-6) receptor monoclonal antibody tocilizumab.

207 Interleukin-6 (IL-6) and IL-6 receptor mRNA and protein have been reported in dif

208 Similarly, IL-6 receptor mRNA histostaining was increased in osteoc

209 se transcriptase-PCR analysis indicated that IL-6 receptor mRNA was present in all carcinoma cell lin

210 6 showed a significant reduction in IL-6 and IL-6 receptor mRNA, together with significant decreases

211 sed to study the effects of dexamethasone on IL-6 receptor number in the well-differentiated human he

212 Neutralization of IL-6 receptor on ECs abolished the ability of HCMV secre

213 Activated T cells expressed lower levels of IL-6 receptors on their surfaces, yet there were suffici

214 rs (CRP, GlycA, IL-6, IL-6 receptor, soluble IL-6 receptor) on cognitive measures (above) and on gene

215 clast formation stimulated by IL-6 + soluble IL-6 receptor, oncostatin M, or IL-1 but not by parathyr

216 This explains why mice lacking the IL-6 receptor only in osteoblasts exhibit a deficit in e

217 mor necrosis factor (TNF) and interleukin-6 (IL-6) receptor, only 20 to 30% of patients experience re

218 Either a blocking Ab to the IL-6 receptor or a neutralizing Ab to IL-6 significantly

219 blocked the ability of either IL-6 + soluble IL-6 receptor or oncostatin M to induce RANKL.

220 Hepatocyte-specific ablation of the IL-6 receptor or Stat3, a major downstream effector of I

221 Blocking the IL-6 receptor or the C5 complement pathway reduces relap

222 y receptor-mediated (i.e., TNFalpha, NGF, or IL-6 receptor) or direct activation of protein kinase Ce

223 ceptor IL-6R (sIL-6R); by an antibody to the IL-6 receptor; or by minocycline, which inhibits the mic

224 NP mendelian randomisation using increase in IL-6 receptor plasma protein as an exposure revealed a s

225 cestry-specific, multiple SNP approach using IL-6 receptor plasma protein as an exposure.

226 examined change in the ratio of IL-6:soluble IL-6 receptor pre-intervention, post-intervention, and a

227 It is likely that this upregulation of IL-6 receptors "primes" human liver cells for subsequent

228 DL1-mediated reduction in membrane (m)-bound IL-6 receptor (R) expression, converting progenitor cell

229 deling tested whether increased IL-6:soluble IL-6 receptor ratio post-intervention was associated wit

230 hyperthermia only increased the IL-6:soluble IL-6 receptor ratio post-treatment [F(3,72) = 11.73,p <

231 d 6, such that increases in the IL-6:soluble IL-6 receptor ratio were associated with decreased depre

232 hich blocks leukocyte TNF, TNF receptor, and IL-6 receptor release, also inhibits L-selectin shedding

233 dependently of the gp80 alpha-subunit of the IL-6 receptor, required for hIL-6 signal transduction.

234 The level of soluble human IL-6 receptor (shuIL-6R) in murine serum and fluorescenc

235 STAT3 serves as the mediator of the IL-6 receptor signal and appears to contribute to the tr

236 aft proteins caveolin-1 and flotillin-1, the IL-6-receptor signal transducing chain gp130, the interf

237 p80 (IL-6 receptor [IL-6R]) component of the IL-6 receptor-signal transducer (gp180) complex plays a

238 al protein S6 kinase, respectively) and IL-6/IL-6 receptor signaling (i.e., IL-6 production and signa

239 Blocking IL-6 receptor signaling from Janus kinases to the Stat3

240 at there is activation-induced inhibition of IL-6 receptor signaling in T cells.

241 Activation of the IL-6 receptor signaling pathway may play a role in diffe

242 dentify TRAF5 as a negative regulator of the IL-6 receptor signaling pathway that limits the inductio

243 ory responses, its role in the regulation of IL-6 receptor signaling remains unclear.

244 ignaling-3 (SOCS-3), a negative regulator of IL-6 receptor signaling.

245 lls from SKGNur mice were hyperresponsive to IL-6 receptor signaling.

246 or and are thus unable to respond to classic IL-6 receptor signaling.

247 o investigate the role of the interleukin 6 (IL-6) receptor signaling in the pathogenesis of MCD and

248 c activation of STAT3 by T-cell receptor and IL-6 receptor signals.

249 lpha (TNFalpha) and the soluble interleukin (IL)-6 receptor (sIL-6R), the latter of which drives proi

250 though treatment with either IL-6 or soluble IL-6 receptor (sIL-6R) alone had no effect on VEGF produ

251 cognate IL-6 receptor (IL-6R) or the soluble IL-6 receptor (sIL-6R) and glycoprotein 130 (gp130).

252 Soluble forms of the IL-6 receptor (sIL-6R) bind to the cytokine IL-6 with si

253 tagonist of the interleukin-6 (IL-6)/soluble IL-6 receptor (sIL-6R) complex and selectively inhibits

254 IL-6 and soluble IL-6 receptor (sIL-6R) expression in induced sputum of a

255 ession; however, the addition of the soluble IL-6 receptor (sIL-6R) induced IL-6 transcripts.

256 pproximately twofold higher IL-6 and soluble IL-6 receptor (sIL-6R) levels compared to matched pre-CL

257 s to evaluate the effect of IL-6 and soluble IL-6 receptor (sIL-6R) on hematopoietic and skeletal act

258 Surprisingly, soluble IL-6 receptor (sIL-6R) produced initial decrease of sEPS

259 forms an agonistic complex with the soluble IL-6 receptor (sIL-6R) to activate all cells expressing

260 studies link high levels of IL-6 and soluble IL-6 receptor (sIL-6R) to asthma severity and decreased

261 al fibroblasts treated with IL-6 and soluble IL-6 receptor (sIL-6R) was used to probe a cytokine micr

262 hanced through transsignaling by the soluble IL-6 receptor (sIL-6r), allowing for the pleiotropic cyt

263 liver enzymes, interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), and soluble tumor necrosis facto

264 d respond to IL-6 in the presence of soluble IL-6 receptor (sIL-6R), but the cell surface expression

265 Expression of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL-10, and IL-13 was detected by

266 production of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL-10, and tumor necrosis factor

267 oteases and receptors, including the soluble IL-6 receptor (sIL-6R), were then quantitated.

268 d secreted significant levels of the soluble IL-6 receptor (sIL-6R).

269 -6 alone and in combination with the soluble IL-6 receptor (sIL-6R).

270 secretion of interleukin (IL)-6 and soluble-IL-6 receptor (sIL-6R).

271 xied inflammatory markers (CRP, GlycA, IL-6, IL-6 receptor, soluble IL-6 receptor) on cognitive measu

272 ore, suppression of Il6ra, the gene encoding IL-6 receptor, specifically in AP neurons with CRISPR/dC

273 dium of cytokine (TNF-alpha and IL-6/soluble IL-6 receptor)-stimulated human cartilage explants.

274 athecal treatment with antisense directed to IL-6 receptor subunit gp130 (gp130), but not to tumor ne

275 in the endothelium for the expression of the IL-6 receptor subunit, IL-6 signal transducer (IL6ST; gp

276 with colitis was increased 80-fold, and the IL-6 receptor subunits IL-6R alpha and gp130 were presen

277 Patients with genetic deficiencies of the IL-6 receptor suffer from "hyper IgE syndrome."

278 enhanced effects observed when combined with IL-6 receptor targeting.

279 b (TCZ) is a humanized monoclonal anti-human IL-6 receptor that inhibits IL-6-mediated proinflammator

280 26 variants in the gene encoding the IL-6R (IL-6 receptor) that proxied for pharmacological IL-6R in

281 To mark the tenth anniversary of anti-IL-6 receptor therapy worldwide, we discuss the history

282 Moreover, addition of soluble interleukin-6 (IL-6) receptor to the medium endowed IL-6 with the abili

283 onal antibodies against CD20 (rituximab) and IL-6 receptor (tocilizumab), the latter also in clinical

284 ane-bound (classic signaling) or the soluble IL-6 receptor (trans-signaling), we first performed cell

285 hagy in myotubes when complexed with soluble IL-6 receptor (trans-signaling).

286 i-IL-6 IMB was far superior to systemic anti-IL-6 receptor treatment in prolonging skin allograft sur

287 pression of IL-6 in combination with soluble IL-6 receptor was a reliable predictor of ALI in SAP.

288 s depleted from MSC conditioned media or the IL-6 receptor was blocked on tumor cells.

289 SHV-positive plasmablasts, whereas the human IL-6 receptor was expressed in most KSHV-positive cells.

290 Immunolabeling studies showed that the IL-6 receptor was restricted to the basal membrane of Pa

291 s phosphorylated after IL-6 binding to gp80 (IL-6 receptor), we hypothesized that gp130 could be invo

292 1 and 2), as well as interleukin (IL)-6 and IL-6 receptor were measured on a daily, weekly and month

293 recruits microglial cells to provide soluble IL-6 receptor, which can form complexes with IL-6.

294 well as signaled by increased pSTAT3 via the IL-6 receptor, which inhibits IRS 1/2 phosphorylation.